ONCSQ — OncoSec Medical Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$1.39m
Annual income statement for OncoSec Medical, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2018 July 31st | 2019 July 31st | 2020 July 31st | 2021 July 31st | 2022 July 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 38.6 | 30.4 | 43.4 | 47.4 | 37 |
Operating Profit | -38.6 | -30.4 | -43.4 | -47.4 | -37 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -39.1 | -30.3 | -43.1 | -47.6 | -37.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -39.1 | -30.3 | -42.3 | -45.2 | -34.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -39.1 | -30.3 | -42.3 | -45.2 | -34.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -39.1 | -30.3 | -42.3 | -45.2 | -34.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -203 | -94.4 | -56.2 | -30.6 | -19.1 |